Mylan lands biosimilar sucker punch to Amgen’s blockbuster
June 6, 2018Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …
AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer
June 5, 2018Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer
In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …
NICE recommends MSD’s Keytruda for advanced PD-L1-positive lung cancer
June 5, 2018Research and Development MSD, Merck, NHS, NICE, keytruda, pharma
UK drug watchdog NICE has chosen to issue final guidance recommending the use of MSD’s Keytruda (pembrolizumab) on the NHS …
Eli Lilly’s President of Oncology to retire
June 5, 2018Research and Development Cancer, Eli Lilly, appointment, oncology, pharma
Just as it ramps up its cancer-fighting efforts, Eli Lilly has revealed that its Senior Vice President and President of …
Novartis’ US Oncology head makes leap to become biotech CEO
June 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis
The departure of high-level, big pharma executives to tiny biotechs is steadily becoming a constant stream; the latest is Bill …
Celgene bring in new CFO to steady the ship
June 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene
The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …
Axovant snatches Teva and Allergan execs to strengthen management
June 5, 2018Manufacturing and Production, Medical Communications Allergan, Axovant, Teva, appointment, pharma
Axovant has announced reinforcements to its management team with two new additions, snatching up Allergan’s current Chief Medical Officer Dr …
FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats
June 5, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma
Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …
FDA links intragastric balloons to 5 more deaths, bringing total to 12 since 2016
June 5, 2018Manufacturing and Production, Sales and Marketing FDA, gastric balloon, pharma
Five more deaths have been reported to the FDA in patients using intragastric balloon systems, meaning that 12 total deaths …
“Underwhelming” drug data devastates Nektar, shares fall by 42%
June 5, 2018Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma
Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …
Janssen debuts promising new cancer data at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, J&J, JJ, Jassen, erdafitinib, imbruvica, pharma
Janssen took the opportunity at the American Society of Clinical Oncology (ASCO) annual event to present promising new Phase 2 …
Roche’s breast, lung cancer offerings fail to impress at ASCO
June 4, 2018Research and Development, Sales and Marketing ASCO, Cancer, Roche, breast cancer, lung cancer, pharma, taselisib, tecentriq
Roche made an underwhelming impact at the American Society of Clinical Oncology (ASCO) annual event in Chicago, after revealing data …
Milan’s decision to appeal the EMA HQ relocation explained
June 4, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Milan, biotech, drugs, pharma, pharmaceutical
The decision to award the EMA headquarters to Amsterdam was a contentious one, not least because the vote had to …
Amgen/Novartis migraine med gets CHMP nod
June 4, 2018Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …
Keytruda offers significant hope in subset of prostate cancer
June 4, 2018Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, prostate cancer
Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …
Celgene bring in new CFO to steady the ship
June 4, 2018Medical Communications, Sales and Marketing Celgene, Johnson & Johnson, biotech, drugs, pharma, pharmaceutical
The fact that Celgene is currently sailing through choppy waters is no secret to anyone within the industry, it’s facing …
Top Ten most popular articles on Pharmafile.com this week
June 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …
Kitov’s combo gets FDA approval in osteoarthritis and hypertension
June 1, 2018Medical Communications, Sales and Marketing Consensi, FDA, Kitov, US, hypertension, osteoarthritis, pharma
Israeli biopharmaceutical firm is celebrating the approval in the US of Consensi, a combo of the calcium channel blocker amlodipine …
Bayer eyes R&D cuts, as Monsanto deal raises question of focus
June 1, 2018Medical Communications Bayer, biotech, drugs, monsanto, pharma, pharmaceutical
When rumours first started rumbling about a mega-merger between Bayer and Monsanto, one of the major question marks was on …
Roche resigns itself to failure on SMA drug
June 1, 2018Medical Communications Roche, biotech, drugs, pharma, pharmaceutical, spinal muscular atrophy
Roche has announced that it will no longer seek to develop its treatment for spinal muscular atrophy (SMA), olesoxime, after …
